Free cash flow margins ranged from -5.5% in 2026Q1 to 9.7% in 2026Q2, with working capital changes of -$160.1M and +$107.5M indicating that cash conversion depends heavily on receivables timing rather than steady earnings quality.
Ardent Health Inc. (ARDT) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Cash from Operations | 480.26M | 470.51M | 315.03M | 221.7M | -38.36M | 159.59M | 119.47M | 85.78M |
| Operating CF Margin % | - | 7.44% | 5.28% | 4.1% | -0.75% | 3.83% | 3.98% | 4.07% |
| Operating CF Growth % | -9.67% | 49.36% | 42.1% | 677.96% | -124.04% | 33.58% | 39.28% | - |
| Net Income | 146.22M | 230.13M | 299.71M | 128.98M | 265.37M | -143.02M | -35.65M | 14.6M |
| Depreciation & Amortization | 166.42M | 155.7M | 146.29M | 140.84M | 138.17M | 143.19M | 109.53M | 71.51M |
| Stock-Based Compensation | 33.3M | 39.29M | 17.98M | 904K | 611K | 0 | 0 | 0 |
| Deferred Taxes | 3.07M | 43.59M | 24.04M | 4M | 46.12M | -7.82M | 49.7M | -12.71M |
| Other Non-Cash Items | 23.7M | 5.13M | 8.76M | 3.29M | -478.89M | 152.7M | 45.83M | 43.08M |
| Working Capital Changes | 22.94M | -3.34M | -181.75M | -56.31M | -9.74M | 14.54M | -49.94M | -30.71M |
| Change in Receivables | 33.43M | 59.16M | 40M | -181.1M | -17.18M | -9.05M | -63.82M | -17.72M |
| Change in Inventory | 5.12M | -3.15M | -9.41M | 1.67M | 4.67M | -1.03M | -3.61M | 56K |
| Change in Payables | -2.15M | 62.06M | -103.86M | 136.82M | 14.42M | 37.15M | 41.3M | -9.28M |
| Cash from Investing | -193.45M | -214.23M | -220.46M | -137.98M | 46.58M | -482.14M | -966.93M | -64.83M |
| Capital Expenditures | -150.76M | -211.9M | -187.51M | -137.41M | -151.11M | -160.66M | -121.53M | -80.5M |
| CapEx % of Revenue | 2.34% | 3.35% | 3.14% | 2.54% | 2.95% | 3.86% | 4.05% | 3.82% |
| Acquisitions | -2.5M | -2.5M | -31.25M | 0 | 206.37M | -349.83M | -857.55M | -2.5M |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -40.18M | 179K | -1.71M | -575K | -8.69M | 28.35M | 12.16M | 18.17M |
| Cash from Financing | -131.63M | -103.47M | 24.64M | -102.26M | -270.33M | 353.22M | 826.81M | -25.89M |
| Debt Issued (Net) | -22.23M | -7.99M | -104.77M | -7.03M | -16.41M | 252.63M | 718.51M | -5.67M |
| Equity Issued (Net) | -24.01M | 0 | 208.66M | 0 | 0 | 99.12M | 143.94M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -174.81M | 0 | 0 | 0 |
| Share Repurchases | -24.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -85.39M | -95.48M | -79.24M | -95.24M | -79.11M | 1.47M | -35.64M | -20.22M |
| Net Change in Cash | 156.8M | 152.82M | 119.21M | -18.55M | -262.11M | -12.3M | -20.65M | -4.95M |
| Free Cash Flow | 280.69M | 258.61M | 127.52M | 84.29M | -189.47M | -1.07M | -2.06M | 3.62M |
| FCF Margin % | 4.35% | 4.09% | 2.14% | 1.56% | -3.69% | -0.03% | -0.07% | 0.17% |
| FCF Growth % | 81.22% | 102.8% | 51.28% | 144.49% | -17590.57% | 48.06% | -156.96% | - |
| FCF per Share | 1.98 | 1.83 | 0.96 | 0.59 | -1.32 | -0.01 | -0.01 | 0.03 |
| FCF Conversion (FCF/Net Income) | 1.92x | 3.46x | 1.50x | 4.41x | -0.20x | -1.12x | -3.35x | 5.87x |
| Interest Paid | 0 | 0 | 74.98M | 81.61M | 90.85M | 86.54M | 64.63M | 26.01M |
| Taxes Paid | 0 | 0 | 41.6M | 19.43M | 55.82M | 5.55M | 2.37M | 23.62M |
Quick answers to the most common questions about buying ARDT stock.
Ardent Health Inc. (ARDT) generated $470.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Ardent Health Inc. (ARDT) generated $258.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Ardent Health Inc. (ARDT) spent $211.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Working capital reversals and earnings gap
Metrics are mathematically derived from official filings.
Operating Cash Flow Diverges From Earnings
Based on reported figures, ARDT's operating cash flow has swung widely against net income, with OCF/NI ratios ranging from negative 1.51 in 2026Q1 to 11.64 in 2026Q2, indicating that quarterly cash conversion is driven more by timing than by steady earnings quality.
The extreme quarter-to-quarter ratios suggest that reported net income is a poor predictor of cash generation for this company over short windows. Investors should monitor whether the 2026Q2 spike, which coincided with a $107.5M working capital inflow, reverses in subsequent periods, as the Q1 negative OCF despite positive earnings implies receivables or other balances absorbed significant cash. This pattern warrants further investigation into the underlying drivers of working capital before treating any single quarter as representative of normalized conversion.
Working Capital Swings Dominate Cash Generation
As reported in financial statements, ARDT's working capital change of negative $160.1M in 2026Q1 and negative $127.5M in 2025Q1 contrasts sharply with inflows of $107.5M and $83.1M in other quarters, suggesting receivables timing is a principal driver of reported cash flow volatility.
The recurring first-quarter outflows in both 2025 and 2026 suggest a possible seasonal pattern in receivables collection or payer settlement timing rather than a one-time event. Because the company's revenue has held near $1.6B, the magnitude of these swings relative to the revenue base implies that collection efficiency is a material variable for free cash flow. Without disclosure of days sales outstanding or self-pay bad debt trends, the cause of these reversals cannot be confirmed from the supplied data.
Free Cash Flow Margins Remain Thin and Volatile
According to reported earnings, ARDT's free cash flow margin ranged from negative 5.5% in 2026Q1 to 9.7% in 2026Q2, with the trailing sequence failing to establish a consistent upward trajectory across the ten reported quarters.
Free cash flow generation appears highly dependent on the working capital cycle rather than on a stable operating base, which limits its usefulness as a standalone valuation anchor. The most recent quarter's 4.5% margin, while positive, sits below the 2026Q2 peak and suggests that the favorable Q2 result was not sustained. Investors should treat trailing free cash flow with caution until multiple consecutive quarters confirm a durable margin level.
Capital Spending Remains Moderate Against Revenue
Based on ARDT's reported figures, capital expenditures have ranged from 1.5% to 5.2% of revenue across recent quarters, with the 2024Q4 and 2025Q4 peaks of roughly 5% suggesting periodic facility or equipment investment cycles rather than uniform maintenance spend.
Quarterly D&A of roughly $37M to $43M sits below the peak CapEx quarters, suggesting that the company has at times invested above its depreciation base, which may indicate growth or modernization spending alongside maintenance needs. The data does not separate maintenance from growth capital, so the portion of spending that is discretionary cannot be determined from the supplied figures. The lumpiness of these outlays appears to amplify the volatility already present in operating cash flow.
Reported Cash Strength May Overstate Durability
The strongest bear case is that ARDT's positive free cash flow in several quarters depends heavily on working capital inflows, which may reverse, leaving underlying cash generation weaker than headline quarterly results suggest.
Cumulative free cash flow across the ten quarters is materially less stable than any single strong quarter implies, with multiple negative FCF periods offsetting the positive ones. Combined with a thin net margin of 2.1% and a debt-to-equity ratio of 1.34, limited earnings cushion could constrain the company's ability to absorb a prolonged working capital drag. Investors should monitor whether reported cash flow improvements persist without reliance on timing benefits from receivables.